A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease

Trial Profile

A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Selonsertib (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 20 Oct 2016 According to Gilead Sciences media release, Data from this study will be submitted for presentation at upcoming scientific conference.
    • 20 Oct 2016 Primary endpoint has not been met.
    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top